Launching Longevity: Funding the Fountain of Youth

Can technology make human longevity a reality? As the pace of discovery accelerates, scientists and entrepreneurs are closing in on the Fountain of Youth. Disrupting the aging process by hacking the code of life, promises better health and longer maximum lifespans. With many layers of complexity from science to ethics, there are still skeptics placing odds against human longevity.

Venture capitalists are betting on success; putting big money on the table to fund longevity startups. Google/Alphabet and drugmaker AbbVie have invested $1.5 billion on Calico, while Human Longevity Inc. recently raised $220 million from their Series B funding round. Complementing traditional venture investment, VCs like Peter Thiel and Joon Yun have established foundations and prizes to accelerate the end of aging.

Why are VCs suddenly investing heavily in longevity startups? Will extended lifespan be a privilege of the wealthy or will the benefits be accessible to all? How long before these well-funded startups bring viable products to market?

Join us on June 21 to hear our panel of leading experts discuss the science and business of human longevity.

Special Presenter:
Aubrey de Grey, Chief Science Officer and Co-founder, SENS

Moderator:
Sonia Arrison, author, “100 Plus: How the Coming Age of Longevity Will Change Everything…”

Panelists:
Dr. Brian Kennedy, CEO, Buck Institute for Research on Aging
Dr. Daniel Kraft, Founder of RegenMed Systems and Chair of Medicine, Singularity University
Will Eden, Vice President, Thiel Capital
Joe McCracken, VP of Business Development, Alkahest
Dr. Thomas Rando, Director of the Glenn Center for the Biology of Aging, Stanford University